FRASSOLDATI, ALICE
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 315
EU - Europa 150
AS - Asia 77
AF - Africa 1
OC - Oceania 1
Totale 544
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 310
IE - Irlanda 46
IT - Italia 29
HK - Hong Kong 26
CN - Cina 25
GB - Regno Unito 25
SE - Svezia 22
SG - Singapore 13
FI - Finlandia 6
CA - Canada 5
BG - Bulgaria 4
DE - Germania 4
ID - Indonesia 4
VN - Vietnam 4
BE - Belgio 3
TR - Turchia 3
ES - Italia 2
FR - Francia 2
NL - Olanda 2
AU - Australia 1
CZ - Repubblica Ceca 1
GR - Grecia 1
IN - India 1
MY - Malesia 1
NG - Nigeria 1
PL - Polonia 1
RO - Romania 1
UA - Ucraina 1
Totale 544
Salva come PNG Salva come JPEG
Città #
Chandler 54
Dublin 46
Fairfield 42
Ashburn 28
Hong Kong 26
Woodbridge 21
Houston 20
Nyköping 20
Cambridge 17
Seattle 15
Ann Arbor 14
San Diego 14
Southend 14
Wilmington 11
Singapore 9
Modena 8
Helsinki 6
Princeton 6
Shanghai 5
Des Moines 4
Dong Ket 4
Jakarta 4
Sofia 4
Kilburn 3
Rome 3
Toronto 3
Wuhan 3
Bremen 2
Brussels 2
Eugene 2
Gazi 2
Guangzhou 2
London 2
Los Angeles 2
Nanjing 2
Norwalk 2
Ottawa 2
Pisa 2
Redwood City 2
Shenzhen 2
Albiate 1
Athens 1
Beijing 1
Boardman 1
Brno 1
Changsha 1
Chicago 1
Chiswick 1
Cupertino 1
Denver 1
Fremont 1
Groningen 1
Hangzhou 1
Hounslow 1
Laurel 1
Lucca 1
North Bergen 1
Para 1
Parma 1
Torino 1
Turin 1
Unirea 1
Vigevano 1
Wandsworth 1
Totale 454
Salva come PNG Salva come JPEG
Nome #
Practice patterns regarding drains management in breast surgery: Results of a survey of Senonetwork Italia breast centers 159
Erratum to: Tumor-infiltrating lymphocytes and molecular response after neoadjuvant therapy for HR+/HER2− breast cancer: results from two prospective trials (Breast Cancer Research and Treatment, (2017), 163, 2, (295-302), 10.1007/s10549-017-4191-y) 137
9 weeks versus 1 year adjuvant trastuzumab for HER2+ early breast cancer: Subgroup analysis of the ShortHER trial allows to identify patients for whom a shorter trastuzumab administration may have a favourable risk/benefit ratio 105
Trastuzumab-lapatinib as neoadjuvant therapy for HER2-positive early breast cancer: Survival analyses of the CHER-Lob trial 88
Everolimus plus aromatase inhibitors as maintenance therapy after first-line chemotherapy: Final results of the phase III randomised MAIN-A (MAINtenance Afinitor) trial 64
Totale 553
Salva come PNG Salva come JPEG
Categoria #
all - tutte 3.232
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 3.232
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/202019 0 0 0 0 0 0 0 0 0 0 11 8
2020/2021142 9 2 12 6 7 5 41 23 10 10 8 9
2021/2022127 3 20 1 4 2 12 9 1 19 11 33 12
2022/2023172 11 25 7 13 11 19 2 14 62 0 2 6
2023/202476 2 5 6 4 13 2 14 12 0 3 5 10
2024/202517 9 0 3 5 0 0 0 0 0 0 0 0
Totale 553